All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Security
Security
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter

California physician and practice pay $6.7M to settle allegations of unnecessary vascular procedures on Medicare patients

By

Michael Walter

8d ago· 1 min readenNews

Summary

A California physician, Dr. Feliciano Serrano, and his practice (Serrano Kidney & Vascular Access Center) have agreed to pay $6.7 million to settle allegations that they performed medically unnecessary vascular procedures on Medicare patients from 2016 to 2024. The settlement includes $6.51 million to the U.S. and nearly $229,000 to California. The physician was accused of pressuring patients into unnecessary dialysis access interventions, including angioplasty and stent placements. One patient allegedly received 42 stents over eight years.

Source

Twitter / XCalifornia physician and practice pay $6.7M to settle allegations of unnecessary vascular procedures on Medicare patientscardiovascularbusiness.com

Key quotes

· 3 pulled
Physician Feliciano Serrano, MD, the owner of Serrano Kidney & Vascular Access Center in Huntington Park, California, was accused of performing a variety of medically unnecessary dialysis access interventions—including angioplasty and stent procedures—on Medicare patients from 2016 to 2024.
One patient allegedly received 42 different stents over an eight-year period.
The physician was accused of pressuring Medicare patients into undergoing treatment they did not need.
Snippet from the RSS feed
The physician was accused of pressuring Medicare patients into undergoing treatment they did not need. One patient allegedly received 42 different stents over an eight-year period.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.